BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Seborrheic Dermatitis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Seborrheic Dermatitis
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07683806-11037@assetmemo.bio
DTSTAMP:20261121T005343Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Roflumilast (Zoryve foam): Phase 3 readout est. (NCT07683806)
DESCRIPTION:Roflumilast (Zoryve foam)\, phase 3\, Seborrheic Dermatitis.\nS
 tudy: Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants W
 ith Seborrheic Dermatitis\nEstimated primary completion: 30 June 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/roflumilast-zoryve-foam#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0768
 3806
URL:https://assetmemo.bio/drug/roflumilast-zoryve-foam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
